1. Byrd J, Dodge R, Carroll A, Baer M, Edwards C, Stamberg J, Quimsieh M, Moore J, Mayer R, Davey F, Schiffer C, Bloomfield C (1999) Patients with t(8;21) (q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose Cytarabine are administered. JCO 17:3767–3775
2. Carella AM, Santini G, Martinengo M, Marmont AM (1984) 4-Demethoxy-daunorubicin (idarubicin) in refractory or relapsed acute leukaemias. Haematologica. Nov-Dec;69(6):767–8
3. Casazza AM, Pratesi G, Giuliani F, Di Marco A (1980) Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori. Oct 31;66(5):549–64
4. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Buchner T (1990) Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 4(3):184–8
5. Kantarjan H (2000) Principles of treatment of newly-diagnosed AML. Leukemia Insights vol. 5 No 4: 4